

Products, Technologies and Markets Worldwide in the Clinical Management of Obesity

- 208 pages
- 65 Exhibits
- 33 Company Profiles
- Published September 2004
- Report #S800



This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity. The report describes the current and projected patient population in obesity, detailing their incidence worldwide, the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and provides current and forecast of the market for these products in the U.S., Canada, Western European countries, Japan and ROW. The report profiles 20 companies in this market, detailing their current products, products in development, market position and overall businesses in obesity management.

Table of Contents

EXECUTIVE SUMMARY

SECTION 1: INTRODUCTION

- 1.1 Overview
- 1.2 Definitions
- 1.3 Clinical Background
 - 1.3.1 Prevalence in the US Population
 - 1.3.2 Prevalence of Obesity Worldwide
 - 1.3.2.1 Europe
 - 1.3.2.2 Japan
 - 1.3.2.3 China
 - 1.3.2.4 Developed Nations vs. Developing Nations
- 1.4 Patient Population Segmentation
 - 1.4.1 Adults
 - 1.4.2 Adolescents
 - 1.4.3 Children
- 1.5 Overweight, Obesity and Morbidity
 - 1.5.1 The Multifactorial Causes of Obesity
 - 1.5.1.1 The Appetite Regulatory System—Facts and Theories
 - 1.5.1.1.1 Insulin
 - 1.5.1.1.2 Leptin: The Ups and Downs of a Promising Lead
 - 1.5.1.1.3 Ghrelin
 - 1.5.1.1.4 Peptide YY & the Y2 Receptor
 - 1.5.1.1.5 AMPK
 - 1.5.1.1.6 Role of the Hypothalamus
 - 1.5.1.1.7 Melanocortins & Serotonin
 - 1.5.1.2 The Body's Fight to Retain Fat
 - 1.5.1.3 Body Mass Index (BMI)
 - 1.5.1.4 Genetic Roots of Obesity
 - 1.5.1.4.1 Congenital Leptin Deficiency
 - 1.5.1.4.2 Genetic Association Studies
 - 1.5.1.4.3 Genetic Testing For Obesity
 - 1.5.2 Obesity, Lifestyle and the 'Obesogenic' Environment
 - 1.5.2.1 Feeding Control
 - 1.5.2.2 Energy Efficiency
 - 1.5.2.3 Adipose Tissue Biology
 - 1.5.2.4 Abdominal Girth as a Warning Sign
 - 1.5.3 Metabolic Syndrome, or Syndrome X
 - 1.5.4 Binge Eating Disorder (BED)
 - 1.5.5 Night Eating Syndrome (NES)

1.5.6 Why Treat Obesity?

SECTION 2: WEIGHT LOSS MANAGEMENT APPROACHES

- 2.1 Surgical Approaches
 - 2.1.1 Background and Professional Certification Efforts
 - 2.1.2 Gastric Bypass, Mini Gastric Bypass and Laparoscopic Surgery
 - 2.1.2.1 Gastric Bypass, or Roux-en-Y Surgery
 - 2.1.2.2 Mini Gastric Bypass
 - 2.1.2.3 Laparoscopic Surgery
 - 2.1.3 Biliopancreatic Diversion/Duodenal Switch (BPD/DS)
 - 2.1.4 Two-Stage Weight Loss Surgery
 - 2.1.5 Vertical Banded Gastroplasty (VBG)
 - 2.1.6 Adjustable Gastric Band (AGB) Surgery
 - 2.1.7 Internal or Implantable Gastric Stimulation (IGS) Device
 - 2.1.8 Gastric Balloon
 - 2.1.9 Radio-frequency Antralplasty
 - 2.2 Pharmaceutical Therapies
 - 2.2.1 Pancreatic Lipase Inhibitors
 - 2.2.2 Serotonin and Norepinephrine Reuptake Inhibitors
 - 2.2.3 Noradrenergic Anorectic Agents
 - 2.3 Non-pharmacological Approaches
 - 2.4 Medically Supervised Very Low Calorie Diets (VLCDs), Behavior Modification and Residential Programs
 - 2.5 Weight Maintenance Approaches
- ### SECTION 3: IMPACT OF OBESITY
- 3.1 Obesity Treatments, Related Costs and Reimbursement
 - 3.2 Impact Upon Business/Economy
 - 3.2.1 United Kingdom
 - 3.2.2 Impact Upon Insurance Costs
 - 3.2.3 Cost of Treatment of Obesity, versus Long-term Cost to Treat Related Conditions
 - 3.3 The Government Enters the Fray
 - 3.3.1 USA
 - 3.3.1.1 Insurance and Mandated Coverage Bills
 - 3.3.1.2 Medicare Debates Gastric Bypass Surgery
 - 3.3.2 United Kingdom: NICE & Weight Management at the Primary Care Level

3.3.3 France: The Caisse Nationale d'Assurance Maladie (CNAM)

SECTION 4: MARKET ASSESSMENT

- 4.1 Bariatric Surgery Devices
 - 4.1.1 United States and Canada
 - 4.1.2 Canada
 - 4.1.3 European Union
 - 4.1.3.1 United Kingdom
 - 4.1.3.2 France
 - 4.1.3.3 Germany
 - 4.1.3.4 Italy
 - 4.1.3.5 Spain
 - 4.1.3.6 Scandinavia
 - 4.1.4 Japan
 - 4.1.5 Rest of World (ROW)
- 4.2 Pharmaceuticals
 - 4.2.1 United States and Canada
 - 4.2.2 Pharmaceutical treatments in the Europe Union
 - 4.2.2.1 United Kingdom
 - 4.2.2.2 France
 - 4.2.2.3 Germany
 - 4.2.2.4 Italy
 - 4.2.2.5 Spain
 - 4.2.2.6 Scandinavia
 - 4.2.3 Japan
 - 4.2.4 Rest of World (ROW)
 - 4.2.5 Developing Drugs for Tomorrow, While Maximizing Profits Today

SECTION 5: OPPORTUNITIES

- 5.1 Drug & Device Market Opportunities
- 5.2 Durable Medical Equipment for the Bariatric Patient
- 5.3 Creating Mutually Beneficial Relationships
- 5.4 Focus on Education and Practice Consulting

SECTION 6: SELECTED COMPANY PROFILES

- 6.1 Abbott Laboratories
- 6.2 AdipoGenix
- 6.3 Amgen
- 6.4 Amylin Pharmaceuticals
- 6.5 AstraZeneca
- 6.6 Athersys, Inc.
- 6.7 Bayer AG
- 6.8 Biovitrum AB
- 6.9 CuraGen Corporation
- 6.10 DeCODE Genetics
- 6.11 DeveloGen AG

- 6.12 Ethicon Endo-Surgery/Johnson & Johnson
- 6.13 GenWay Biotech, Inc.
- 6.14 GlaxoSmithKline
- 6.15 Inamed Corporation
- 6.16 Ingenium Pharmaceuticals AG
- 6.17 IntraPace, Inc.
- 6.18 Johnson & Johnson
- 6.19 Manhattan Pharmaceuticals, Inc.
- 6.20 Merck & Co., Inc.
- 6.21 Metabolic Pharmaceuticals Ltd
- 6.22 Millennium Pharmaceuticals
- 6.23 Myriad Genetics
- 6.24 Natesth Pharmaceutical Company, Inc.
- 6.25 Pfizer, Inc.
- 6.26 Regeneron Pharmaceuticals
- 6.27 Roche (F Hoffman-La Roche Ltd)
- 6.28 Sanofi-Aventis
- 6.29 Speedel Group AG
- 6.30 Synovis Life Technologies Inc.
- 6.31 Transneuronix, Inc.
- 6.32 Vista Medical Technologies, Inc.
- 6.33 Wyeth Pharmaceuticals

APPENDIX: LIST OF COMPANIES
APPENDIX: LIST OF
ORGANIZATIONS

List of Exhibits

- Exhibit 1-1: Elements Contributing to the Obesity Epidemic
- Exhibit 1-2: Prevalence of Obesity, Percent of Population (2003)
- Exhibit 1-3: WHO Graph of Obesity, 2004
- Exhibit 1-4: Worldwide Total, Obese and Morbidly Obese, 2002-2013
- Exhibit 1-5: Examples of Definitions Used and Age Groups Included in Surveys Reporting Prevalence of Obesity
- Exhibit 1-6: Examples of Human Pleiotropic Obesity Syndromes
- Exhibit 1-7: Leptin's Role in the Body
- Exhibit 1-8: Candidate Genes for Control of Appetite, Energy Expenditure, Usage of Nutrients and Body Fat Distribution
- Exhibit 2-1: IFSO and Minimum Professional Requirements for Practicing Bariatric Surgeon
- Exhibit 2-2: Gastric Bypass Surgery
- Exhibit 4-1: Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US\$M)
- Exhibit 4-2: Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US\$M)
- Exhibit 4-3: Bariatric Surgery Devices, Total Market Forecast, 2002-2013

- Exhibit 4-4: Medical Devices, Market Forecast, United States and Canada, 2002-2013
- Exhibit 4-5: Bariatric Surgery Devices, Market Forecast, US and Canada, 2002-2013
- Exhibit 4-6: US Obesity Treatment Medical Device Company Market Shares, 2013
- Exhibit 4-7: Medical Devices, Market Forecast, European Union, 2002-2013
- Exhibit 4-8: Medical Devices, Market Forecast, United Kingdom, 2002-2013
- Exhibit 4-9: Bariatric Surgery Devices, Market Forecast, United Kingdom 2002-2013
- Exhibit 4-10: Medical Devices, Market Forecast, France, 2002-2013
- Exhibit 4-11: Bariatric Surgery Devices, Market Forecast, France, 2002-2013
- Exhibit 4-12: Adjustable Gastric Band Device Market Shares, France, 2004
- Exhibit 4-13: Medical Devices, Market Forecast, Germany, 2002-2013
- Exhibit 4-14: Bariatric Surgery Devices, Market Forecast, Germany 2002-2013
- Exhibit 4-15: Medical Devices, Market Forecast, Italy, 2002-2013
- Exhibit 4-16: Bariatric Surgery Devices, Market Forecast, Italy 2002-2013
- Exhibit 4-17: Medical Devices, Market Forecast, Spain, 2002-2013
- Exhibit 4-18: Bariatric Surgery Devices, Market Forecast, Spain 2002-2013
- Exhibit 4-19: Medical Devices, Market Forecast, Scandinavia, 2002-2013
- Exhibit 4-20: Bariatric Surgery Devices, Market Forecast, Scandinavia 2002-2013
- Exhibit 4-21: Medical Devices, Market Forecast, Japan, 2002-2013
- Exhibit 4-22: Bariatric Surgery Devices, Market Forecast, Japan 2002-2013
- Exhibit 4-23: Medical Devices, Market Forecast, Rest of World, 2002-2013
- Exhibit 4-24: Bariatric Surgery Devices, Market Forecast, ROW 2002-2013
- Exhibit 4-25: Total Pharmaceutical Sales, Market Forecast, 2002-2013
- Exhibit 4-26: Obesity Drugs, Market Forecast, USA and Canada, 2002-2013
- Exhibit 4-27: Obesity Drugs, Market Forecast, USA and Canada, 2002-2013
- Exhibit 4-28: Obesity Drugs, Market Forecast, European Union, 2002-2013
- Exhibit 4-29: Obesity Drugs, Market Forecast, United Kingdom, 2002-2013

- Exhibit 4-30: Obesity Drugs, Market Forecast, United Kingdom, 2002-2013
- Exhibit 4-31: Obesity Drugs, Market Forecast, France, 2002-2013
- Exhibit 4-32: Obesity Drugs, Market Forecast, France, 2002-2013
- Exhibit 4-33: Obesity Drugs, Market Forecast, Germany, 2002-2013
- Exhibit 4-34: Obesity Drugs, Market Forecast, Germany, 2002-2013
- Exhibit 4-35: Obesity Drugs, Market Forecast, Italy, 2002-2013
- Exhibit 4-36: Obesity Drugs, Market Forecast, Italy, 2002-2013
- Exhibit 4-37: Obesity Drugs, Market Forecast, Spain, 2002-2013
- Exhibit 4-38: Obesity Drugs, Market Forecast, Spain, 2002-2013
- Exhibit 4-39: Obesity Drugs, Market Forecast, Scandinavia, 2002-2013
- Exhibit 4-40: Obesity Drugs, Market Forecast, Scandinavia, 2002-2013
- Exhibit 4-41: Obesity Drugs, Market Forecast, Japan, 2002-2013
- Exhibit 4-42: Obesity Drugs, Market Forecast, Japan, 2002-2013
- Exhibit 4-43: Obesity Drugs, Market Forecast, ROW, 2002-2013
- Exhibit 4-44: Obesity Drugs, Market Forecast, ROW, 2002-2013
- Exhibit 5-1: Potential Market Alliances in Obesity
- Exhibit 6-1: Abbott Laboratories 2003 Sales by Division
- Exhibit 6-2: Johnson & Johnson and Subsidiaries, Division of Sales by Segment, 2003
- Exhibit 6-3: Inamed Corporation Sales, 2003
- Exhibit 6-4: Johnson & Johnson Worldwide Sales, 2003
- Exhibit 6-5: Johnson & Johnson Sales by Geographic Region, 2003
- Exhibit 6-6: Pfizer Divisions by Revenues, Fourth Quarter 2003
- Exhibit 6-7: Pfizer Drug Division Revenues as Percent of Total Human Pharmaceutical Revenues, Fourth Quarter 2003
- Exhibit 6-8: Roche Sales by Region, 2003
- Exhibit 6-9: Sanofi-Aventis 2003 Consolidated Sales
- Exhibit 6-10: Synovis Life Technologies Sales by Product Group, 2003

To purchase, complete the form below and mail or fax to:
 51 Fairfield, Foothill Ranch, CA 92610 USA
 Tel: (949) 859-3401 **Fax: (949) 837-4558.**

Name: _____
 Title: _____
 Company: _____
 Address: _____
 City: _____ State/Province: _____ ZIP-Postal: _____ Country: _____
 Phone: _____ Fax: _____ Email: _____

Please send me "Clinical Management of Obesity", report S800:

- US **\$2,450** print or PDF (circle one or add \$200 for both).
 - Add \$1,500 for a site license (unlimited number of users per company location)
- OR Add \$2,500 for a global license (unlimited number of users per company)

- Enclosed is my check* Invoice my company (PO# _____)
- Charge my: Visa MasterCard American Express

Name on Card _____ Signature _____
 Card number _____ Expiration date _____

*Make checks payable to *MedMarket Diligence*. CA customers add tax of 7.75%.